Biogen Increases Profit Potential on Investigational Alzheimer’s Disease Treatment Aducanumab Through Amended Agreement with Neurimmune Holding AG Oct 27, 2017 Life Science
China blue-chips rally to 26-month high as new leadership line-up unveiled Oct 26, 2017 Life Science, Technology
ONCLIVE: Novel Alkylating Agent Defies Mechanisms of Resistance in GBM Tumors Oct 25, 2017 Life Science
Resverlogix Announces Right of First Refusal Agreement with Hepalink USA Inc. Oct 24, 2017 Life Science
